Login

RFPs & Calls for Grant Applications

Current RFPs and Call for Grant Applications
  • 24 Apr 2017 11:34 AM | Anonymous

     

    Release Date: April 14, 2017

    A Focus on the Issues: Historically, veterinary pathologists have played a key role as scientific investigators in addition to their contributions as diagnostic pathologists, teachers, and research collaborators, which is why research is considered to be a crucial element of best practices in pathology training.1-4 Nevertheless, data obtained from the American College of Veterinary Pathologists (ACVP) suggest that for several decades now, there has been a slowing or decrease of the number of veterinary pathologists and in particular veterinary pathologists with research training despite the calls for increase in the numbers of those veterinary scientists.

    Please read the attachment for complete Notification:

         CGN_gRAF Vet Path_2Qtr2017.pdf

     

  • 21 Apr 2017 1:29 PM | Anonymous

    Release Date: April 14, 2017

    A Focus on the Issues: In recent years, several issues have emerged that are critical to defining future directions for the scientific projects that enable systems to use translational or implementation research to improve patient care. There exists a growing body of research that highlights the ineffectiveness of a ‘one size fits all’ approach to treatment. Research cited in the international weekly journal of science, Nature1, revealed the limited reach of therapeutics, noting that of the ten most popular drugs prescribed in the U.S., some ultimately reach as few as one in 25 eligible patients.1 Today’s healthcare practitioners and their research counterparts remain accountable, but they are continuously challenged to understand myriad factors that influence a person’s care: medical records, genetic profile, environmental & social background, and other elements. As a result, a majority of healthcare plans continue to be made with insufficient data, hindering a healthcare system’s ability to address qualified gaps. Furthermore, it takes, on average, seventeen years for clinical evidence to fully integrate into practice; additionally, 20% of core information guiding clinical decisions changes within one year.

         Please see attachment for complete Grant Notification:

               CGN_gRAF Precision Care_2Qtr2017.pdf

              

     

  • 20 Apr 2017 2:04 PM | Anonymous

    Release Date: April 14, 2017

    A Focus on the Issues: Informed clinicians are essential to promoting positive patient outcomes. On average 20% of the core information guiding clinical decisions typically change within one year because of the appropriate tide of consistently emerging data.1 Healthcare practices and their clinicians are challenged with preparing to efficiently absorb new information that could impact their care decisions with patients. Clinicians often seek a more efficient information infrastructure to better connect them to data exposure, and evaluating emerging evidence-based information for their patients and families. With emerging data in therapeutic areas offering preference sensitive treatments, shared decision making (SDM) and patient engagement is a valuable method that can help improve satisfaction and ultimately improve2 patient outcomes, and lower costs of care.3-5 Unfortunately, while SDM is supported in the reformed healthcare marketplace focused on developing higher quality care, it is poorly adopted by clinicians today, and the care patients receive may not necessarily align to their preferences.

                        Please see attachment for complete Notification:

                                CGN IME Emerging Areas_2Qtr2017.pdf

     

     

  • 20 Apr 2017 12:31 PM | Jim Ranieri (Administrator)

    Pfizer
    Independent Grants for Learning & Change

    Call for Grant Applications (CGA)
    Advances in the Treatment of Renal Cell Carcinoma
     
    Date CGA Issued: April 19, 2017
    Clinical Area: Renal Cell Carcinoma
    Geographic Scope: United States, Europe
    Link to full CGA: Advances in the Treatment of Renal Cell Carcinoma
    Due Date: May 31, 2017
     
    Specific Area of Interest:  It is our intent to support continuing professional development programs (CME/CE) for medical oncologists, urologists, nurses, nurse practitioners, physician assistants and other healthcare professionals involved in the care and treatment of patients with RCC. Proposed programs should focus on understanding adjuvant therapy in oncology. Other topics of interest are current and future treatment sequencing with tyrosine-kinase inhibitors (TKIs) and adverse event management for patients with RCC.
     
    Questions regarding this CGA should be directed to derek.warnick@pfizer.com.

  • 12 Apr 2017 1:41 PM | Jim Ranieri (Administrator)

    Pfizer Independent Grants for Learning & Change
    Request for Proposals (RFP)
    Strategies to Support Increasing Exercise and
    Activity in Haemophilia Patients
     
    Date RFP Issued: April 10, 2017
    Clinical Area: Haemophilia
    Strategies to Support Increasing Exercise & Activity in Haemophilia Patients
    Letter of Intent Due Date: June 5, 2017
    Geographic Region: Europe, Japan, Australia, and New Zealand
     
    Specific Area of Interest:
    It is our intent to support projects that focus on the importance of physical activity in haemophilia patients as part of the approach to the management of haemophilia. In particular, we are keen to support projects that encourage patients to partake in appropriate physical activity, taking into account the individual patient’s bleeding history, physical status, age, interests and social requirements. The objective is to improve patients’ physical wellbeing, their pain perception, their quality of life (QoL) and their illness behavior.
     
    Multi-disciplinary collaborations, are encouraged when appropriate, but all partners must have a relevant role in the proposed project.
     
    It is expected that projects will be evidence-based (education and/or quality improvement) and the proposed research/evaluation will follow generally accepted scientific principles.
     
    Refer to complete details in the Full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jo Habron (jo.harbron@pfizer.com).

  • 31 Mar 2017 3:29 PM | Anonymous

    THERAPUTIC AREA:  Ophthalmology  - Vitreoretinal Fellowship

    Grant requests are due to REGENERON no later than Monday, May 1, 2017

    View complete RFP

      

  • 22 Mar 2017 12:02 PM | Jim Ranieri (Administrator)

    Pfizer RFP: Immuno-Oncology - Pan-tumor
    LOI Due Date: May 1, 2017

    View complete RFP
  • 26 Jan 2017 9:13 AM | Jim Ranieri (Administrator)

    View Genentech document with call for grant notifications released January 23, 2017

Powered by Wild Apricot Membership Software